ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

AZN Astrazeneca Plc

10,878.00
-146.00 (-1.32%)
16 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Astrazeneca Plc LSE:AZN London Ordinary Share GB0009895292 ORD SHS $0.25
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -146.00 -1.32% 10,878.00 10,884.00 10,886.00 10,966.00 10,822.00 10,882.00 1,307,341 16:35:20
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 45.81B 5.96B 3.8415 28.34 168.75B
Astrazeneca Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker AZN. The last closing price for Astrazeneca was 11,024p. Over the last year, Astrazeneca shares have traded in a share price range of 9,461.00p to 12,390.00p.

Astrazeneca currently has 1,550,189,338 shares in issue. The market capitalisation of Astrazeneca is £168.75 billion. Astrazeneca has a price to earnings ratio (PE ratio) of 28.34.

Astrazeneca Share Discussion Threads

Showing 5576 to 5596 of 6150 messages
Chat Pages: Latest  234  233  232  231  230  229  228  227  226  225  224  223  Older
DateSubjectAuthorDiscuss
13/2/2022
13:56
Beckers, thanks for the IC article.
philanderer
13/2/2022
10:03
Neither approved by Swissmedic who concluded that their data did not support the benefit/risk equation. AZN then (I believe) withdrew their submission.
alphorn
13/2/2022
08:59
Apologies if this is slightly off topic but did the AZN covid vaccine ever get approved for use in the US by the FDA? If not, was it due to AZN not really going for it ?TIA
paulboz
11/2/2022
13:03
No problem RR, nice to share good news on AZ, which they thoroughly deserve.

'17 times UBS’s EPS estimates for 2022' that's good value especially with the increase in dividend, gives the market confidence. Well done AZ!

beckers2008
11/2/2022
12:52
Thanks for sharing Beckers. AZ "exceeded all expectations". That's right.
riskonricky
11/2/2022
12:50
Even DZ is getting onside!!!!

DZ Bank Lifts AstraZeneca To Hold From Sell, Boosts Fair Price
02/11/2022 | 12:45pm GMT

beckers2008
11/2/2022
12:41
Nice article in IC which I will now share because it is yesterday's news.

AstraZeneca reaps oncology rewards
The ongoing controversy surrounding the AstraZeneca/Oxford covid vaccine obscures the company’s real success
February 10, 2022
By Julian Hofmann

• Covid vaccine is irrelevant to AstraZeneca's business
• Oncology specialisation makes it a real Euro pharma player

It was a year of highs and lows for AstraZeneca (AZN) which is still with the controversy surrounding the Oxford Covid vaccine as the debate over the impact of the jab and political reactions to it during the pandemic rumbles on. However, investors should not forget that vaccines are not, and were never, a material part of AstraZeneca’s business and that its real value is as an innovative developer of high value oncology medicines in hard-to-treat cancers.

In this respect, the company has exceeded all expectations and with 2021 dominated by positive trial readouts for key products trastuzumab deruxetan (Enhertu) in breast cancer and olaparib (Lynparza) in prostate cancer, the high risk/reward strategy that chief executive Pascal Soriot initiated when he took the helm in mid-2009 looks validated. It is measure of how far and quickly the oncology programme has developed that if you look up how Lynparza was viewed by Astra’s previous management, it was listed prominently as a discontinued programme for breast cancer. More than a decade on and the medicine generated $2.3bn (£1.69bn) in annual sales in these results, a 32 per cent increase on 2020.

With the market still waiting on further data from Astra’s DESTINY-Breast04 trial for Enhertu, developed in partnership with Japanese company Daiichi Sankyo, the full-year results had to be merely in line with everyone’s expectations for the market to be satisfied and Astra did not disappoint. Apart from the trial results, the biggest corporate move of the year was the company’s purchase in July of US biotech Alexion for $41bn, funded by a combination of Astra shares and $8bn in new long-term debt. Investors should expect the company to incur integration costs until 2025, with one-time costs of $2.1bn.

The impact on the balance sheet overall was surprisingly benign, apart from the $8bn increase in goodwill and a doubling of intangible assets post-the acquisition. AstraZeneca seems to have managed to maintain shareholder equity while spending the vast stock of retained earnings that had built up under previous chief executive David Brennan. For example, in 2010, these topped $18bn, but barely $1.7bn in these results.

Despite its generally irritating use of “core” and “non-core̶1; earnings, AstraZeneca is clearly the pharma company of the moment, which is reflected in a forward price/earnings ratio of 17 times UBS’s EPS estimates for 2022. That places Astra at the top table of European pharma valuations, but based on its operational performance, that rating looks eminently justified. Buy.

beckers2008
10/2/2022
15:41
Nice reaction as well. First dividend increase in 10 years, mid to high 20s percentage rise in core earnings expected for 2022, fall in Covid vaccine sales offset by increasing antibody sales. Core earnings per share $1.67 against predicted of $0.73 for the fourth quarter. Looks good.
woodyjmw
10/2/2022
10:48
Yes, continue holding this fella ;-)
philanderer
10/2/2022
07:58
Great results - and finally an increase in dividend to 2.90 USD from 2.80 previously.
bluemango
09/2/2022
08:54
Results tomorrow
bluemango
06/2/2022
13:29
OTTAWA
Freedom Truckers Convoy 2022 Live Feb 5

Party ! Party ! watched this live last night .......fabulous to see

This will make a difference, even Manchester had their own mini convoy lol, the word is spreading

jimarilo
04/2/2022
20:26
Final results due next week, Thurs 10th.

Anyone think there's grounds for saying we'll finally see an increase in dividend after many years unchanged?

Last increase was in 2012.

bluemango
03/2/2022
20:49
I heard rumours on the street that Hedge funds are slowly starting to place short positions on Pfizer and Moderna.
zaxarobal
03/2/2022
15:13
I must be out of date. I thought Emily was a her.
tday
02/2/2022
13:19
Just catching up again!

ASTRAZENECA : Barclays remains its Buy rating
01/31/2022 | 12:34pm GMT

Emily Field from Barclays retains his positive opinion on the stock with a Buy rating. The target price remains unchanged at GBX 11500.

beckers2008
01/2/2022
14:59
Its already been on the record that covid vaccine will offer no profit for the companies involved
prokartace
01/2/2022
12:57
Anybody thinking the bull run in Pharmas could be coming to an end?...or seen the top and distribution going on...
diku
01/2/2022
11:04
That's not good.

Some obviously knew and sold yesterday.

philanderer
30/1/2022
22:22
Full-year and Q4 2021 results on 10th February 2022
gateside
24/1/2022
17:37
pHARMa criminals are starting to take a hit .....their evil is being found out

Better late than never LOL

jimarilo
Chat Pages: Latest  234  233  232  231  230  229  228  227  226  225  224  223  Older

Your Recent History

Delayed Upgrade Clock